Your browser doesn't support javascript.
loading
Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders
Journal of Movement Disorders ; : 136-143, 2016.
Article in English | WPRIM | ID: wpr-180368
ABSTRACT
Gene therapy is a potential therapeutic strategy for treating hereditary movement disorders, including hereditary ataxia, dystonia, Huntington's disease, and Parkinson's disease. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome using modified nucleases. Recently, clustered regularly interspaced short palindromic repeat/CRISPR associated protein 9 (CRISPR/Cas9) has been used as an essential tool in biotechnology. Cas9 is an RNA-guided DNA endonuclease enzyme that was originally associated with the adaptive immune system of Streptococcus pyogenes and is now being utilized as a genome editing tool to induce double strand breaks in DNA. CRISPR/Cas9 has advantages in terms of clinical applicability over other genome editing technologies such as zinc-finger nucleases and transcription activator-like effector nucleases because of easy in vivo delivery. Here, we review and discuss the applicability of CRISPR/Cas9 to preclinical studies or gene therapy in hereditary movement disorders.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Parkinson Disease / Streptococcus pyogenes / Biotechnology / DNA / Genetic Therapy / Genetic Engineering / Spinocerebellar Degenerations / Genome / Huntington Disease / Deoxyribonuclease I Language: English Journal: Journal of Movement Disorders Year: 2016 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Parkinson Disease / Streptococcus pyogenes / Biotechnology / DNA / Genetic Therapy / Genetic Engineering / Spinocerebellar Degenerations / Genome / Huntington Disease / Deoxyribonuclease I Language: English Journal: Journal of Movement Disorders Year: 2016 Type: Article